Outcomes of Treatment and Factors Influencing Prognosis in Ugandan Children with Acute Myeloid Leukaemia - Scorecard - MDSpire

Outcomes of Treatment and Factors Influencing Prognosis in Ugandan Children with Acute Myeloid Leukaemia

  • By

  • Richard Nyeko

  • Mariana Kruger

  • Nixon Niyonzima

  • Barnabas Atwiine

  • Jennifer Zungu

  • Joyce Balagadde Kambugu

  • Stijn Verhulst

  • Jaques van Heerden

  • December 18, 2025

  • 0 min

Share

Clinical Scorecard: Outcomes of Treatment and Factors Influencing Prognosis in Ugandan Children with Acute Myeloid Leukaemia

At a Glance

CategoryDetail
Condition
Key MechanismsChemotherapy combined with multidisciplinary care; genetic abnormalities and minimal residual disease (MRD) negativity as key prognostic factors.
Target Population
Care Setting

Key Highlights

  • mortality_rates_source

Guideline-Based Recommendations

Diagnosis

    Management

    • I
    • n
    • c
    • l
    • u
    • d
    • e
    • s
    • p
    • e
    • c
    • i
    • f
    • i
    • c
    • c
    • h
    • e
    • m
    • o
    • t
    • h
    • e
    • r
    • a
    • p
    • y
    • r
    • e
    • g
    • i
    • m
    • e
    • n
    • s
    • a
    • n
    • d
    • s
    • u
    • p
    • p
    • o
    • r
    • t
    • i
    • v
    • e
    • c
    • a
    • r
    • e
    • m
    • e
    • a
    • s
    • u
    • r
    • e
    • s
    • .

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Expand on the implications of limited access to cytogenetic and molecular analyses.

        Clinical Best Practices

        • supportive_care

        Related Resources & Content

        Original Source(s)

        Outcomes of Treatment and Factors Influencing Prognosis in Ugandan Children with Acute Myeloid Leukaemia

        • by Richard Nyeko, Mariana Kruger, Nixon Niyonzima, Barnabas Atwiine, Jennifer Zungu, Joyce Balagadde Kambugu, Stijn Verhulst, Jaques van Heerden

        • December 18, 2025

        Related Content

        ASCO26: Alicia Morgans, MD, MPH, ARACOG

        Dr. Alicia Morgans of Dana-Farber Cancer Institute reported at #ASCO26 that ARACOG found darolutamide was associated with less decline in cognitive testing than enzalutamide, which may help guide treatment choice.

        • July 1, 2026

        • 1 min
        RFX5 in cancer: context-dependent molecular functions and emerging translational relevance

        ASCO26: Sara Tolaney, MD, MPH, ASCENT-03

        Dana-Farber Cancer Institute's Dr. Sara Tolaney from the ASCENT-03 stud in breast cancer. The data further strengthens the case for approval of sacituzumab govitecan as first-line treatment for patients with advanced triple-negative breast cancer.

        • July 1, 2026

        • 1 min